Tempus ECG-AF vs Vivid T9/Vivid T8
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary goal is to proactively identify older patients (65+) at increased risk of developing new-onset atrial fibrillation within the next year, utilizing existing 12-lead ECG data. This tool is ideal for integrating into routine geriatric or internal medicine screenings to enable earlier intervention and follow-up for high-risk individuals.
View Tempus ECG-AF →Choose Vivid T9/Vivid T8 if…
Choose GE HealthCare's Vivid T9/T8 if you require an advanced, AI-powered cardiovascular ultrasound system for comprehensive real-time diagnostic imaging and functional assessment. This system is best suited for detailed evaluation of cardiac function, including automated ejection fraction and myocardial strain analysis, across cardiology, critical care, and general imaging settings.
View Vivid T9/Vivid T8 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | Vivid T9/Vivid T8 |
|---|---|---|
| Pricing | Contact vendor | Unknown |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Unknown |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Unknown |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Vivid T9/Vivid T8Tool B, the GE HealthCare Vivid T9/T8, emphasizes an ergonomic design with a continuously tiltable HD LCD monitor and multi-touch screen, directly enhancing the user experience for sonographers. Its 'Scan Assist Pro' feature is specifically designed to optimize workflow efficiency and standardize exam procedures, indicating a strong focus on practical usability in a clinical setting.
Clinical Value
Vivid T9/Vivid T8While Tool A offers a specific, FDA-cleared predictive capability for AF risk, Tool B provides a broader suite of AI-powered tools that enhance a wide range of diagnostic measurements and imaging capabilities in cardiovascular ultrasound. Features like Cardiac Auto Doppler, AutoEF, and Automated Function Imaging offer comprehensive clinical utility across multiple aspects of cardiac assessment.
Pricing & Value
Tempus ECG-AFTool A, Tempus ECG-AF, has a clear CMS reimbursement pathway with a specified Medicare rate of $128.90, effective January 1, 2025, which provides a transparent and predictable revenue stream for healthcare providers. In contrast, Tool B is a significant capital expenditure for hardware with variable pricing, making its direct value proposition harder to assess without specific quotes and considering the total cost of ownership.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness through FDA clearance and HIPAA compliance. Tool A is a software solution designed for integration into existing facility systems and explicitly states BAA availability, while Tool B, though hardware-based, supports HIPAA compliance through features like disk encryption and offers DICOM connectivity for data management.
Innovation
Tempus ECG-AFTool A represents a novel application of AI for predictive risk assessment of Atrial Fibrillation from standard ECGs, identifying patients at increased risk of developing AF within the next 12 months. This moves beyond traditional diagnostic interpretation to proactive patient identification, which is a more innovative clinical application of AI compared to Tool B's enhancement of existing ultrasound functionalities.
Support & Docs
Vivid T9/Vivid T8GE HealthCare, as a major medical device manufacturer, has an extensive and well-established global support infrastructure for its hardware products, including service agreements, technical support contacts, and comprehensive documentation libraries for its Vivid ultrasound systems. Tempus AI, while undoubtedly offering support for its software, does not publicly detail its support and documentation offerings to the same extent as a large hardware vendor.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | Vivid T9/Vivid T8 |
|---|---|---|
| Name | Tempus ECG-AF | Vivid T9/Vivid T8 |
| Company | Tempus AI, Inc. | GE HealthCare |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | Advanced cardiovascular ultrasound systems featuring AI-powered tools for enhanced imaging, workflow, and diagnostics across various medical specialties. |
| Primary Function | AI-based algorithm for 12-lead ECG analysis to detect signs associated with new onset Atrial Fibrillation (AF) within 12 months. | Advanced cardiovascular ultrasound imaging with AI-powered tools for enhanced imaging, workflow, and diagnostics. |
| Target Patient Population | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. | Not specified |
| Key AI Features | AI-based algorithm for 12-lead ECG analysis, detects signs associated with new onset Atrial Fibrillation (AF) within 12 months. | AI-based Cardiac Auto Doppler, AutoEF, Automated Function Imaging (AFI), AI Auto Measure (2D & Spectrum Recognition), Scan Assist Pro. |
| CMS Reimbursement | Available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). | Not specified |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Vivid T9/Vivid T8.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-AF or Vivid T9/Vivid T8
Backers
Who funded each tool's parent company.